Evaluation of immune restoration potential of PD-1 Blockers

Journal of Immunoassay and Immunochemistry

Volumn 36, Issue 6, 2015, Pages 567-572

  Liu, Weihuang ^a   Tong, Zan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

drug development; flow cytometry; immune restoration; PD 1 blocker; proliferation index

Indexed keywords

INTERLEUKIN 2; PROGRAMMED DEATH 1 BLOCKER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTIBODY; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ADULT; ANTAGONISTS AND INHIBITORS; EVALUATION STUDY; FEMALE; IMMUNOLOGY; MALE; MONONUCLEAR CELL;

ADULT; ANTIBODIES; ANTIGENS, CD274; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84930904300     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321819.2015.1017104     Document Type: Article

References (8)

1. Dong, H.; Zhu, G.; Tamada, K.; Chen, L. B7-H1, a Third Member of the B7 Family, Co-stimulates T-cell Proliferation and Interleukin-10 Secretion. Nat. Med. 1999, 5(12), 1365-1369.
2. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P. C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 Promotes T-cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat. Med. 2002, 8(8), 793-800.
3. Dolan, D.E.; Gupta, S. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control 2014, 21(3), 231-237.
4. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012, 366(26), 2455-2465.
5. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 2012, 366(26), 2443-2454.
6. Lipson, E.J.; Sharfman, W.H.; Drake, C.G.; Wollner, I.; Taube, J.M.; Anders, R.A.; Xu, H.; Yao, S.; Pons, A.; Chen, L.; Pardoll, D.M.; Brahmer, J.R.; Topalian, S.L. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin. Cancer Res. 2013, 19(2), 462-468.
7. Martin-Orozco, N.; Wang, Y.H.; Yagita, H.; Dong, C. Cutting Edge: Programmed Death (PD) ligand-1/PD-1 Interaction is Required for CD8+ T Cell Tolerance to Tissue Antigens. J. Immunol. 2006, 177(12), 8291-8295.
8. Wallace, P.K.; Tario, J.D., Jr.; Fisher, J.L.; Wallace, S.S.; Ernstoff, M.S.; Muirhead, K.A. Tracking Antigen-Driven Responses by Flow Cytometry: Monitoring Proliferation by Dye Dilution. Cytometry A 2008, 73(11), 1019-1034.